User login
Article Type
Changed
Wed, 05/26/2021 - 13:55
Display Headline
New therapies bring hope after much frustration
Collectively representing numerous distinct cancers, gastrointestinal (GI) malignancies are a major health burden worldwide. Despite the development of numerous targeted therapies that have advanced the treatment of several GI cancer types, current treatment options have afforded only modest improvements in survival. Here, we discuss how valuable insights gained from both successes and failures are fostering hope for new therapies.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 14(2)
Page Number
79-84
Legacy Keywords
gastrointestinal malignancies, gastrointestinal stromal tumors, GIST, imatinib, colorectal cancers, CRC, HER1/EGFR, monoclonal antibody, mAb, trastuzumab, ado-trastuzumab emtansine, erlotinib, gemcitabine, pancreatic cancer, mAbs, panitumumab, cetuximab, KRAS, onartuzumab, mFOLFOX
Sections
Article PDF
Article PDF
Collectively representing numerous distinct cancers, gastrointestinal (GI) malignancies are a major health burden worldwide. Despite the development of numerous targeted therapies that have advanced the treatment of several GI cancer types, current treatment options have afforded only modest improvements in survival. Here, we discuss how valuable insights gained from both successes and failures are fostering hope for new therapies.
Click on the PDF icon at the top of this introduction to read the full article.
Collectively representing numerous distinct cancers, gastrointestinal (GI) malignancies are a major health burden worldwide. Despite the development of numerous targeted therapies that have advanced the treatment of several GI cancer types, current treatment options have afforded only modest improvements in survival. Here, we discuss how valuable insights gained from both successes and failures are fostering hope for new therapies.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 14(2)
Issue
The Journal of Community and Supportive Oncology - 14(2)
Page Number
79-84
Page Number
79-84
Article Type
Display Headline
New therapies bring hope after much frustration
Display Headline
New therapies bring hope after much frustration
Legacy Keywords
gastrointestinal malignancies, gastrointestinal stromal tumors, GIST, imatinib, colorectal cancers, CRC, HER1/EGFR, monoclonal antibody, mAb, trastuzumab, ado-trastuzumab emtansine, erlotinib, gemcitabine, pancreatic cancer, mAbs, panitumumab, cetuximab, KRAS, onartuzumab, mFOLFOX
Legacy Keywords
gastrointestinal malignancies, gastrointestinal stromal tumors, GIST, imatinib, colorectal cancers, CRC, HER1/EGFR, monoclonal antibody, mAb, trastuzumab, ado-trastuzumab emtansine, erlotinib, gemcitabine, pancreatic cancer, mAbs, panitumumab, cetuximab, KRAS, onartuzumab, mFOLFOX
Sections
Citation Override
JCSO 2016;14:79-84
Disallow All Ads
Alternative CME
Article PDF Media
Document